These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Poor response to fluoxetine: underlying depression, serotonergic overstimulation, or a "therapeutic window"? Cain JW J Clin Psychiatry; 1992 Aug; 53(8):272-7. PubMed ID: 1500403 [TBL] [Abstract][Full Text] [Related]
46. Relationship between mirtazapine dose, plasma concentration, response, and side effects in clinical practice. Grasmäder K; Verwohlt PL; Kühn KU; Frahnert C; Hiemke C; Dragicevic A; von Widdern O; Zobel A; Maier W; Rao ML Pharmacopsychiatry; 2005 May; 38(3):113-7. PubMed ID: 15902580 [TBL] [Abstract][Full Text] [Related]
47. Fluoxetine once every third day in the treatment of major depressive disorder. Tural U; Onder E Eur Arch Psychiatry Clin Neurosci; 2003 Dec; 253(6):307-12. PubMed ID: 14714120 [TBL] [Abstract][Full Text] [Related]
48. The effects of renal and hepatic disease on the pharmacokinetics, renal tolerance, and risk-benefit profile of fluoxetine. Bergstrom RF; Beasley CM; Levy NB; Blumenfield M; Lemberger L Int Clin Psychopharmacol; 1993; 8(4):261-6. PubMed ID: 8277145 [TBL] [Abstract][Full Text] [Related]
49. [Plasmatic concentrations of fluoxetine, pharmacokinetics, therapeutic response and side effects]. Pérez Sola V; Pérez Blanco J; Alvárez E; Queralto JM Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1993; 21(4):143-7. PubMed ID: 8213289 [TBL] [Abstract][Full Text] [Related]